Statement of preliminary issues released for Dechra’s application to acquire Osurnia from Elanco

The Commerce Commission has published a statement of preliminary issues relating to an application from Dechra Pharmaceuticals PLC, Dechra Limited and Dechra Veterinary Products LLC seeking clearance to acquire from Elanco Tiergesundheit AG its worldwide assets, rights and liabilities relating to the supply of Osurnia, a treatment for otitis in dogs.

The statement outlines the key competition issues that the Commission considers important in deciding whether or not to grant clearance to the proposed acquisition.

We invite interested parties to provide comments on the likely competitive effects of the proposed acquisition. We request that submissions are received by close of business on 6 May 2020. The Commission acknowledges that some interested parties may face a range of challenges during the current COVID-19 alert levels and the variation of levels as and when they are altered.

/Public Release. The material in this public release comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.